Coral Laboratories files compliance certificate. Coral Laboratories stock returns 32.04 percent

Published on 10/20/2026 at 01:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A September 30 compliance certificate was filed on October 10, 2026. Coral Laboratories stock posted INR 53.90 million profit in June 2026.

Compliance filing and earnings context

Coral Laboratories filed a securities compliance certificate on October 10, 2026.
Profit after tax rose 78.25 percent in the latest six months reported on September 25, 2026.
Coral Laboratories had a market capitalization of INR 1.9 billion as of October 19, 2026.

Coral, INE683E01017, Illustration mit AI erstellt.

Coral Laboratories (ISIN INE683E01017) filed a securities compliance certificate on October 10, 2026, covering the quarter ended September 30. StockFin.ai identified the filing as a certificate under Regulation 74(5) of India's securities rules. For Coral Laboratories stock, the filing adds a regulatory milestone ahead of the next reported results.

Three filings shape the timeline

The recent corporate record shows three separate steps. On September 25, 2026, the board approved the cost audit report for fiscal year 2025-26, with the meeting running from 2:30 p.m. to 2:58 p.m., according to ScanX News.

On September 29, 2026, Coral Laboratories held its 44th annual meeting and proposed a final dividend of INR 2.00 per share for fiscal year 2025-26. The same report said fiscal-year income fell to INR 957.97 million from INR 1,241.14 million, while earnings after tax declined to INR 168.31 million from INR 241.56 million.

What does the June result mean?

The June 2026 quarter supplied a sharper operating counterpoint. MarketsMOJO reported that net sales grew 57.39 percent year over year to INR 296.20 million, while profit after tax rose 110.50 percent to INR 53.90 million. Across the latest six months cited in that report, profit after tax increased 78.25 percent to INR 106.20 million.

The improvement is concentrated in the recent reporting periods rather than the full-year record. MarketsMOJO also cited a five-year annual sales decline of 0.29 percent and return on equity of 7.68 percent, leaving the earnings improvement alongside a longer-term growth question.

BSE valuation and trading context

Coral Laboratories was valued at INR 1.9 billion as of October 19, 2026. Its finance-market quotation was INR 524.80 on the BSE at 3:29 p.m. IST that day, against a 52-week range of INR 360.00 to INR 679.00. The company operates in the healthcare and pharmaceuticals sectors and is listed under BSE scrip 524506.

The next useful marker is the September 30 reporting period covered by the October 10 compliance filing. That date distinguishes the regulatory certificate from the operating figures already reported for June 2026.

Stock context remains tied to results

The filing itself is procedural, but the surrounding figures give it investor relevance. June sales and profit growth were strong, while fiscal-year income and earnings were lower year over year. The next results disclosure will show whether the recent improvement extends beyond one quarter.